Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R G Conway

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Agents and Actions. Supplements|January 1, 1991
C5a structural requirements for neutrophil receptor interactionK W Mollison, T A Fey, R A Krause, et al.
Journal of Medicinal Chemistry|December 23, 1994
N-(acyloxyalkyl)pyridinium salts as soluble prodrugs of a potent platelet activating factor antagonistS K Davidsen, J B Summers, D H Albert, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1996
Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonistD H Albert, R G Conway, T J Magoc, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1995
ABT-299, a potent antagonist of platelet activating factorJ B Summers, D H Albert, S K Davidsen, et al.
European Journal of Pharmacology|December 6, 2001
In vitro activity of LY393558, an inhibitor of the 5-hydroxytryptamine transporter with 5-HT(1B/1D/2) receptor antagonist propertiesI A Pullar, J R Boot, S L Carney, et al.
Journal of Medicinal Chemistry|January 23, 1998
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonistsM L Curtin, S K Davidsen, H R Heyman, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Agents and Actions. Supplements|January 1, 1991
C5a structural requirements for neutrophil receptor interactionK W Mollison, T A Fey, R A Krause, et al.
Journal of Medicinal Chemistry|December 23, 1994
N-(acyloxyalkyl)pyridinium salts as soluble prodrugs of a potent platelet activating factor antagonistS K Davidsen, J B Summers, D H Albert, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1996
Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonistD H Albert, R G Conway, T J Magoc, et al.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research|January 1, 1995
ABT-299, a potent antagonist of platelet activating factorJ B Summers, D H Albert, S K Davidsen, et al.
European Journal of Pharmacology|December 6, 2001
In vitro activity of LY393558, an inhibitor of the 5-hydroxytryptamine transporter with 5-HT(1B/1D/2) receptor antagonist propertiesI A Pullar, J R Boot, S L Carney, et al.
Journal of Medicinal Chemistry|January 23, 1998
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonistsM L Curtin, S K Davidsen, H R Heyman, et al.
Pageof 2